{"id":"deferiprone-matching-placebo-tablets","safety":{"commonSideEffects":[{"rate":null,"effect":"Agranulocytosis"},{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Gastrointestinal disturbances (nausea, vomiting, abdominal pain)"},{"rate":null,"effect":"Arthralgia and arthritis"},{"rate":null,"effect":"Elevated liver enzymes"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Deferiprone is a bidentate chelating agent that forms stable complexes with ferric iron (Fe³⁺), facilitating its urinary and fecal excretion. By reducing labile iron pools and preventing iron-catalyzed free radical formation, it mitigates oxidative damage to organs in patients with chronic iron overload. This mechanism is particularly important in transfusion-dependent anemias where repeated blood transfusions lead to pathological iron accumulation.","oneSentence":"Deferiprone is an iron chelator that binds and removes excess iron from the body, reducing iron-induced tissue damage.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:44:15.721Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Transfusion-dependent iron overload in patients with chronic anemias (e.g., thalassemia major, sickle cell disease)"},{"name":"Iron overload in patients with myelodysplastic syndromes"}]},"trialDetails":[{"nctId":"NCT03234686","phase":"PHASE2","title":"Deferiprone to Delay Dementia (The 3D Study)","status":"COMPLETED","sponsor":"Neuroscience Trials Australia","startDate":"2018-01-19","conditions":"Mild Cognitive Impairment, Prodromal Alzheimer's Disease, Mild Alzheimer's Disease","enrollment":81},{"nctId":"NCT02728843","phase":"PHASE2","title":"Study of Parkinson's Early Stage With Deferiprone","status":"COMPLETED","sponsor":"ApoPharma","startDate":"2016-10-12","conditions":"Parkinson's Disease","enrollment":140},{"nctId":"NCT01391520","phase":"PHASE3","title":"Efficacy and Safety of Deferiprone in Patients With Chronic Kidney Disease Undergoing a Cardiac Catheterization and Receiving Contrast Agent","status":"WITHDRAWN","sponsor":"CorMedix","startDate":"2012-01","conditions":"Acute Kidney Injury","enrollment":""},{"nctId":"NCT01860703","phase":"PHASE4","title":"Evaluation of Whether Deferiprone Affects QT Interval in Healthy Subjects","status":"COMPLETED","sponsor":"ApoPharma","startDate":"2012-11","conditions":"Prolonged QTc Interval","enrollment":50}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Placebo"],"phase":"marketed","status":"active","brandName":"deferiprone matching placebo tablets","genericName":"deferiprone matching placebo tablets","companyName":"ApoPharma","companyId":"apopharma","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Deferiprone is an iron chelator that binds and removes excess iron from the body, reducing iron-induced tissue damage. Used for Transfusion-dependent iron overload in patients with chronic anemias (e.g., thalassemia major, sickle cell disease), Iron overload in patients with myelodysplastic syndromes.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}